Authors

Latest:

Dr. Cardoso on the Global mBC Vision 2025 Call-to-Action

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Champalimaud Clinical Cancer Center, discusses the Global mBC Vision 2025 Call-to-Action.

Fausto Roila, MD

Latest:

Dr. Roila on Aprepitant for the Prevention of Cisplatin-Induced Delayed Emesis

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

Federico Aucejo, MD

Latest:

First Liver Transplant Surgery Performed in Patient With CRC Metastases

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Federico Ustaris, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Felix M. Chinea, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Ferdinandos Skoulidis, MD, PhD, MRCP

Latest:

Dr Skoulidis on the Methods of Analyzing KRAS G12C Inhibitor Efficacy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the methods utilized in a retrospective study that investigated molecular determinants of KRAS G12C inhibitor efficacy in patients with advanced non–small cell lung cancer.

Filip Janku, MD, PhD

Latest:

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

Filipa Lynce, MD

Latest:

Dr Lynce on Ongoing Trials Evaluating Novel Combinations in Inflammatory Breast Cancer

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Filippo Pietrantonio, MD

Latest:

Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr Pietrantonio

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Fiona McCaughan, RN, MS

Latest:

Facilitating Intraperitoneal Chemotherapy Completion

Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion

Floor J. Backes, M

Latest:

Dr. Backes on Pelvic Exenteration Surgery in Gynecologic Cancer

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

Floor J. Backes, MD

Latest:

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

Forrest Thompson, MD

Latest:

Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

Fortunato Ciardiello, MD, PhD, Second University of Naples

Fortunato Ciardiello, MD, PhD, Seconda Universita di Napoli

Frances Valdes-Albini, MD

Latest:

Dr. Valdes-Albini Discusses Trials in HER2+ Breast Cancer

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Francesca Gay, MD, PhD

Latest:

Dr Gay on Efficacy Findings From the IsKia Trial in Multiple Myeloma

Francesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.

Francesco Forconi, MD

Latest:

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

Francesco Lo-Coco, MD

Latest:

Dr. Francesco Lo-Coco on Arsenic Trioxide in APL

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Francine Foss, MD

Latest:

Dr Foss on the FDA Approval of Denileukin Diftitox for CTCL

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.